• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Black Titan Corporation

    2/20/26 9:00:16 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BTTC alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of February 2026

     

    Commission File No. 001-42880

     

    BLACK TITAN CORPORATION

    (Registrant’s Name)

     

    Level 8, Unit 8-02 The Bousteador, 10, Jalan PJU 7/6
    Mutiara Damansara, 47800 Petaling Jaya
    Selangor Darul Ehsan, Malaysia(Address of Principal Executive Offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    Change in Registrant’s Certifying Accountant

     

    On January 29, 2026, the audit committee (the “Audit Committee”) of the board of directors of Black Titan Corporation (the “Company”) approved the change of the Company’s independent registered public accounting firm from Enrome LLP (“Enrome”) to Guangdong Prouden CPAs GP (“Guangdong Prouden”). The engagement with Enrome ended as of January 30, 2026, and the engagement of Guangdong Prouden became effective as of February 13, 2026. The change was approved by the Audit Committee of the Company’s board of directors. The Company’s decision of the dismissal was not the result of any disagreement between the Company and Enrome on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure.

     

    The principal accountant’s report of the Enrome on the financial statements of the Company as of and for the fiscal years ended July 31, 2025 and 2024 did not contain any adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles. Enrome was engaged in 2024.

     

    From May 2024 through the date of dismissal, (i) there were no “disagreements” (as described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Enrome on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to Enrome’s satisfaction, would have caused Enrome to make reference to the subject matter of the disagreement(s) in connection with its report to the subject matter of the disagreement; and (ii) there were no “reportable events” of the type described in Item 304(a)(1)(v) of Regulation S-K, except for the material weaknesses related to the Company’s internal control over financial reporting, including (i) lack of accounting staff and resources with appropriate knowledge of accounting principles generally accepted in the U.S. GAAP and SEC reporting and compliance requirements to design and implement formal period-end financial reporting policies and procedures to address complex technical accounting issue in accordance with GAAP and the SEC requirements, and (ii) lack of information technology general controls in the areas of IT policies and procedures, user provisioning and termination, privileged access and service organization monitoring who are responsible for change management over certain core business system and accounting system

     

    We furnished a copy of the disclosures in this report to Enrome and requested that Enrome furnish us with a letter addressed to the SEC stating whether such firm agrees with the above statements or, if not, stating the respects in which it does not agree. A copy of the letter has been furnished as an exhibit to this report as Exhibit 16.1.

     

    During the two most recent fiscal years and the subsequent interim period through February 13, 2026, neither the Company nor anyone on its behalf consulted with Guangdong Prouden regarding (i) the application of accounting principles to a specified transaction, either completed or proposed; the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided that Guangdong Prouden concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and its related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K). Guangdong Prouden is aware of the material weaknesses described above and understands it is a reportable event.

     

    Exhibits

     

    Exhibits No.   Description
         
    16.1   Letter of Enrome, regarding change in independent registered public accounting firm.

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Black Titan Corporation
         
      By: /s/ Chay Weei Jye
      Name: Chay Weei Jye
      Title: Co-Chief Executive Officer

     

    Dated: February 20, 2026

     

    3

    Get the next $BTTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BTTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BLACK TITAN CORPORATION APPOINTS CZHANG LIN AS CO-CHIEF EXECUTIVE OFFICER

    NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Black Titan Corporation (NASDAQ:BTTC) (the "Company" or "Black Titan") today announced the appointment of Czhang Lin as Co-Chief Executive Officer, further strengthening the Company's leadership team as it accelerates its strategic expansion into the digital asset and blockchain sectors. Mr. Lin brings deep expertise in the cryptocurrency and blockchain ecosystem, with a track record of investing in and advising high-growth Web3 projects around the world since 2017. He has collected a vast network over the last 8 years by investing in projects or taking key roles in various funds, that include Binance labs and now currently serves as investment

    11/12/25 8:30:00 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Titan Corporation seeks to explore Long-Term Strategic Crypto Initiatives with potential Strategic Investments in Digital Currencies

    NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Black Titan Corporation. (NASDAQ:BTTC) (the "Company" or "Black Titan"), today announced plans to seek long-term strategic crypto initiatives with potential strategic investments in digital currencies. Black Titan is exploring the utilization of a digital currency holding strategy to invest in and capitalize on cryptocurrency opportunities. Black Titan is actively exploring additional investments to expand its portfolio through direct coin acquisitions, mining, and fintech-related mergers and acquisitions. Chay W. J., CEO of Black Titan, remarked, "The approach of leveraging debt, equity, and cash flow to build Crypto holdings has delivered stro

    10/6/25 4:15:00 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan Corporation

    NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. ("Titan" or "TTNP") today announced the successful closing of its previously announced merger with Black Titan Corporation ("Black Titan") and TalenTec Sdn. Bhd. ("TalenTec"). Following the merger, the combined company's ordinary shares, $0.0001 par value per share, will trade on the Nasdaq stock exchange under the ticker symbol NASDAQ: BTTC. Pursuant to the Merger and Contribution and Share Exchange Agreement dated August 19, 2024, Titan has become a wholly owned subsidiary of Black Titan Corporation, effective as of October 1, 2025. As part of the transaction, each issued and outstanding share of Titan common stock

    10/3/25 5:26:00 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTTC
    SEC Filings

    View All

    SEC Form 6-K filed by Black Titan Corporation

    6-K - Black Titan Corp (0002034400) (Filer)

    2/20/26 9:00:16 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Black Titan Corporation

    6-K - Black Titan Corp (0002034400) (Filer)

    2/19/26 4:15:01 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Black Titan Corporation

    6-K - Black Titan Corp (0002034400) (Filer)

    2/12/26 6:56:11 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTTC
    Leadership Updates

    Live Leadership Updates

    View All

    BLACK TITAN CORPORATION APPOINTS CZHANG LIN AS CO-CHIEF EXECUTIVE OFFICER

    NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Black Titan Corporation (NASDAQ:BTTC) (the "Company" or "Black Titan") today announced the appointment of Czhang Lin as Co-Chief Executive Officer, further strengthening the Company's leadership team as it accelerates its strategic expansion into the digital asset and blockchain sectors. Mr. Lin brings deep expertise in the cryptocurrency and blockchain ecosystem, with a track record of investing in and advising high-growth Web3 projects around the world since 2017. He has collected a vast network over the last 8 years by investing in projects or taking key roles in various funds, that include Binance labs and now currently serves as investment

    11/12/25 8:30:00 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care